NEW YORK (GenomeWeb) – Bio-Techne announced today that it has agreed to acquire Advanced Cell Diagnostics for $250 million in cash, plus an additional consideration of $75 million if certain milestones are achieved.

The deal is expected to close on or about August 1, and will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne said it expects to obtain. The company expects the acquisition to be slightly dilutive to its adjusted earnings per share for fiscal year 2017, and accretive thereafter.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.